Galectin Therapeutics to Present at 2015 Ladenburg Thalmann Healthcare Conference
September 22 2015 - 10:00AM
Galectin Therapeutics (Nasdaq:GALT), the leading developer of
therapeutics that target galectin proteins to treat fibrosis and
cancer, announced today that Peter G. Traber, M.D., chief executive
officer, president, and chief medical officer of Galectin
Therapeutics, will make a corporate presentation at the 2015
Ladenburg Thalmann Healthcare Conference on September 29th at 11
a.m. Eastern Time. The conference is being held at the Sofitel
Hotel in New York City.
To listen to the presentation, investors may visit the investor
relations section of Galectin Therapeutics' website at
www.galectintherapeutics.com. An archived audio of the presentation
will also be available on Galectin Therapeutics' website for 90
days.
About Galectin Therapeutics
Galectin Therapeutics is developing promising carbohydrate-based
therapies for the treatment of fibrotic liver disease and cancer
based on the Company's unique understanding of galectin proteins,
which are key mediators of biologic function. Galectin seeks to
leverage extensive scientific and development expertise as well as
established relationships with external sources to achieve
cost-effective and efficient development. The Company is pursuing a
development pathway to clinical enhancement and commercialization
for its lead compounds in liver fibrosis and cancer. Additional
information is available at www.galectintherapeutics.com.
Galectin Therapeutics and its associated logo is a registered
trademark of Galectin Therapeutics Inc.
CONTACT: Jack Callicutt, Chief Financial Officer
(678) 620-3186
ir@galectintherapeutics.com.
LHA
Kim Golodetz
(212) 838-3777
kgolodetz@lhai.com
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Apr 2023 to Apr 2024